ClinicalTrials.gg
RecruitingNCT07160153CANAAUpdated Nov 2, 2026

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

An observational study in Cannabis Dependence, Harmful Use and Cognitive Assessment, sponsored by University Hospital Pilsen. Recruiting at 1 site in Czechia. Open to participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionMarijuana Abuse(the registry's first term)UnverifiedIs this wrong?The registry often attaches Marijuana Abuse to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University Hospital Pilsen · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
29
Ages
15 Years to 18 Years
Sex
All
01

Study summary

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Read the detailed description

Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.

02

Conditions studied

  • Cannabis Dependence
  • Harmful Use
  • Cognitive Assessment

Browse trials for

Keywords

  • Cannabis Dependence
  • Cannabis Use Disorder
  • Abstinence
  • Cognitive Function
  • Disorder; Abstinence; Cognitive Function; Neuropsychological
03

In context

Marijuana Abuse Unverified

188 studies on the registry are indexed under Marijuana Abuse; 26 are open to participants now.

This study's planned enrollment of 29 is below the median of 100 across 20 observational studies indexed under Marijuana Abuse.

Browse Marijuana Abuse studies →

Lead sponsor

University Hospital Pilsen is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Compared within Marijuana Abuse, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Exclusion criteria

Exclusion Criteria:

  • psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
  • somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
  • Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
29 participants (estimated)
Target follow-up
2 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group 1

    Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

    Diagnostic Test: Neurocognitive assessment · Diagnostic Test: Urine toxicological assessment

Interventions

  • Diagnostic testNeurocognitive assessment

    Neurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs Other psychometrics: The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)

  • Diagnostic testUrine toxicological assessment

    Urine toxicological assessment

06

What researchers measure

Primary outcomes

  1. Change in performance TMT-B

    Change in performance on the Trail Making Test - Part B (TMT-B) \[Time Frame: after 8 weeks of abstinence from cannabis\]

    Time frame: 8 weeks

Secondary outcomes

  1. Change in performance on AVLT

    Change in performance on the Auditory Verbal Learning Test (AVLT) \[Time Frame: after 8 weeks of abstinence\]

    Time frame: 8 weeks

  2. Change in performance on the Stroop Test

    Change in performance on the Stroop Test \[Time Frame: after 8 weeks of abstinence\]

    Time frame: 8 weeks

  3. Change in performance on the Tower of London

    Change in performance on the Tower of London (Shallice version) \[Time Frame: after 8 weeks of abstinence\]

    Time frame: 8 weeks

  4. Change in performance on CPT-IP

    Change in performance on the Continuous Performance Test - Identical Pairs (CPT-IP) \[Time Frame: after 8 weeks of abstinence\]

    Time frame: 8 weeks

Other outcomes

  1. Cannabis Abuse Screening Test versus degree of neurocognitive impairment

    Correlation between severity of cannabis dependence (Cannabis Abuse Screening Test, CAST) and degree of neurocognitive impairment \[Time Frame: baseline and after 8 weeks of abstinence\]

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Not decided yet because we are still recruiting and waiting for primary outcome.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 8, 2025
StartActual
Dec 3, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Aug 31, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07160153
Lead sponsor
University Hospital Pilsen
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Dec 3, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Jiri Podlipny, MD, Ph.D.
Contact
podlipny@fnplzen.cz
+420 377 103 209
Frantisek Nekvapil, MD
Contact
nekvapilfr@fnplzen.cz
+420 377 103 101

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion